United KingdomResearchers have developed a light-activated compound, BIN-3I, designed to combat antibiotic-resistant bacteria such as MRSA. This compound uses beta-lactamase—an enzyme produced by resistant bacteria—to activate a photosensitizer upon exposure to infrared light, allowing it to accumulate within the bacteria and kill them. Unlike previous methods where active agents dispersed too quickly, this new approach includes hydrophilic components that prevent premature activation and improve targeting. The compound remains inactive in non-resistant bacteria and mammalian cells until acted upon by beta-lactamase, making it more selective and potentially safer. The findings were published in the Proceedings of the National Academy of Sciences.
Bias read (Center): The article discusses scientific research on combating antibiotic resistance, focusing on technical details of a new compound. It does not present any political positions, controversies, or ideological perspectives. The content is purely scientific and neutral in tone.
